184 related articles for article (PubMed ID: 21586625)
21. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L; Petrini M; Granato AM; Gentilcore G; Simeone E; Ascierto PA; Pancisi E; Ancarani V; Fiammenghi L; Guidoboni M; de Rosa F; Valmorri L; Scarpi E; Nicoletti SV; Baravelli S; Riccobon A; Ridolfi R
J Transl Med; 2013 May; 11():135. PubMed ID: 23725550
[TBL] [Abstract][Full Text] [Related]
22. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
23. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
24. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J
BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057
[TBL] [Abstract][Full Text] [Related]
25. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
26. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
29. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
30. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
32. Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.
Ramirez AG; Wages NA; Hu Y; Smolkin ME; Slingluff CL
Cancer Immunol Immunother; 2015 Dec; 64(12):1531-9. PubMed ID: 26392296
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
[TBL] [Abstract][Full Text] [Related]
34. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
35. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
36. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.
Van Nuffel AM; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2012 Jul; 61(7):1033-43. PubMed ID: 22159452
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
38. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
40. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]